Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk ER-positive/HER2-negative primary breast cancer
NL-OMON52593Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer and ductal breast carcinoma comparing Nivolumab arm with Placebo arm (2 arms). Primary endpoints: Event-free survival and Pathological complete response. Started Mar 2021; status: completed.
02
Drugs
03
Conditions
breast cancerductal breast carcinoma
Beyond the preview
Go deeper on NL-OMON52593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52593.